A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma

The combination of 5‐fluorouracil (5‐FU), leucovorin (LV), and oxaliplatin (l‐OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant. This allowed the authors to intensify the three‐drug chronotherapy regimen and to assess its activity as the initial treatment of metastatic colorectal carcinoma patients in ten centers from four countries.

[1]  F. Lévi,et al.  Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[3]  D. Sargent,et al.  Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Lévi,et al.  Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.

[5]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Lévi,et al.  Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Kerr,et al.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. Lévi,et al.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. , 1996, Annals of surgery.

[9]  F. Lévi.  Chronotherapy for gastrointestinal cancers. , 1996, Current opinion in oncology.

[10]  F. Lévi,et al.  Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.

[11]  G Milano,et al.  Spontaneous or imposed circadian changes in plasma concentrations of 5‐fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer , 1994, Clinical pharmacology and therapeutics.

[12]  R. Diasio,et al.  Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. , 1993, Cancer research.

[13]  R. Sothern,et al.  Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. , 1992, Blood.

[14]  A. Reinberg,et al.  A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.

[15]  P. Duffey,et al.  The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Sothern,et al.  Circadian rhythm of cellular proliferation in the human rectal mucosa. , 1991, Gastroenterology.

[17]  O D Laerum,et al.  DNA synthesis in human bone marrow is circadian stage dependent. , 1991, Blood.

[18]  A. Reinberg,et al.  Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. , 1989, Cancer research.

[19]  Hryniuk Wm.  The importance of dose intensity in the outcome of chemotherapy. , 1988 .

[20]  W. Hryniuk.  The importance of dose intensity in the outcome of chemotherapy. , 1988, Important advances in oncology.